As part of our ongoing commitment to quality improvement UK NEQAS for Leucocyte Immunophenotyping is keen to obtain the views of participants on the quality of samples issued in the flow cytometry programmes operated by this centre and acquire feedback on the continuing development of the Leukaemia Immunophenotyping programme. We would be extremely grateful if participants registered in the flow cytometry programmes could complete this survey, which can be accessed by clicking on the following link
Unfortunately, the survey cannot be saved prior to submission but we envisage that the survey should take approximately 10 minutes to complete.
All information submitted by participants will remain the property of UK NEQAS LI and will not be divulged to any other 3rd party. However, it may be presented in a generic form in presentations and/or publications.
There are 2 weeks remaining to re-register for 2017/18. Please click here and log in to your account to re-register.
For more information, please email email@example.com
As a result of an internal review, we have taken the decision to adjust the performance monitoring limits for quantitative programmes.
These will be rolled out on an ongoing basis until all such quantitative programmes are amended.
Listed below are the current quantitative programmes where the changes have been made. This will be updated as and when changes to any programmes are made and show the trial and date when the changes came into effect.
|BCR-ABL1 Major Quantification||161702||13/09/2016|
|Post SCT Chimerism Monitoring||161703||26/10/2016|
|Low Level Leucocyte Enumeration||161708||16/01/2017|
|CD34+ Stem Cell Enumeration||161705||23/01/2017|
Immune Monitoring Alternative Technologies
|Minimal Residual Disease for Acute Lymphoblastic Leukaemia||161704||24/01/2017|
|Pilot Minimal Residual Disease in AML||161703||07/02/2017|
|Pilot Minimal Residual Disease in CLL||161703||13/02/2017|
|Leukaemia Immunophenotyping (Part 1)||161705||21/02/2017|
The changes to the performance limits detailed below will be applicable to all quantitative programmes appearing in the above list unless otherwise specified.
• A result between 2.5 and -2.5 will now be classed as satisfactory
• A result between >2.5 and 3.5 or <-2.5 and -3.5 will be classed as an 'Action’ result. An ‘Action’ category highlights a potential issue to the laboratory and indicates that the laboratory should review. Two ‘Action’ results in a period of 3 samples would result in classification as a ‘Critical’
• A result above 3.5 or below -3.5 is considered to be a ‘critical’ result requiring immediate investigation by the laboratory
Please note that if you are a UK-based laboratory the relevant National Quality Assurance Advisory Panel will be automatically notified when a Critical level of performance is assigned. Non-UK laboratories are not notified to UK NQAAP’s.
UK NEQAS for Leucocyte Immunophenotyping (UK NEQAS LI) now has a Facebook page and a Twitter account. We will be posting important messages to these accounts relating to our schemes so please like or follow us, respectively.
We hope that these feeds will act as a useful eductational resource for participants and collaborators alike, collating interesting papers, conference info, videos and news stories in haemato-oncology. As we develop our online presence we hope to publish some of our own educational content. If you have any feedback or ideas as to content you would like us to include, please do not hesitate to get in touch.